Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
For a patient with RA-ILD and an UIP pattern, which treatment would you prefer: tocilizumab or abatacept?
Related Questions
What criteria do you use to decide when to perform a BAL in hypersensitivity pneumonitis?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
How do you determine whether to add abatacept or rituximab to the treatment regimen in patients with mild RA-ILD on methotrexate?
What immunosuppression regimens do clinicians use in patients with progressive RB-ILD despite smoking cessation and prednisone?
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
What factors do you consider when determining whether to perform a biopsy for the diagnosis of organizing pneumonia?
Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?
